Endometriosis Recurrence After Surgery
Endometriosis recurs rapidly after surgery, with recurrence rates reaching 17% at 12 months and 27% at 24 months in women not receiving postoperative hormonal suppression. 1
Recurrence Timeline and Rates
The speed of endometriosis recurrence depends critically on whether postoperative hormonal suppression is used:
Without Postoperative Hormonal Treatment
- 4% recurrence at 3 months 1
- 14% recurrence at 6 months 1
- 17% recurrence at 12 months 1
- 27% recurrence at 24 months 1
- Up to 44% of women experience symptom recurrence within one year after surgery 2
These rates come from a 2024 systematic review and meta-analysis of 55 studies including over 5,000 patients, representing the highest quality evidence on this question. 1
With Postoperative Hormonal Suppression
Hormonal suppression dramatically reduces recurrence risk, with a 59% relative risk reduction (RR 0.41,95% CI: 0.26-0.65) compared to expectant management. 3
Critical Risk Factors for Faster Recurrence
Certain factors predict more rapid recurrence after surgery:
Highest Risk Factors:
- History of previous endometriosis surgery (OR 8.2) - the strongest predictor of recurrence 4
- Bilateral endometriomas (OR 6.4) 4
- Left-sided endometriomas (OR 2.7) 4
- Tender nodules at cul-de-sac (OR 2.2) 4
- Higher postoperative r-AFS scores (OR 1.2 per point increase) 4
Protective Factors:
- Postoperative pregnancy (OR 0.25) - most protective factor 4
- Postoperative progesterone for 6 months (OR 0.52) 4
- Older age at surgery (OR 0.94 per year) 4
Prevention Strategy: Postoperative Hormonal Suppression
All patients not seeking immediate pregnancy should receive postoperative hormonal suppression to prevent recurrence. 3
First-Line Options (Equally Effective)
- Combined oral contraceptives - continuous use preferred 2, 3
- Progestins (oral medroxyprogesterone acetate or megestrol acetate) 5, 3
- Levonorgestrel-releasing intrauterine system (LNG-IUS) 5, 3
All three options show consistent decreased risk of recurrence in high-quality studies. 3
Second-Line Option
- GnRH agonists for at least 3 months with mandatory add-back therapy to prevent bone mineral loss 2, 5
Treatment Duration
Hormonal suppression should be initiated within 6 weeks postoperatively and continued long-term, as 25-34% experience recurrent pelvic pain within 12 months of discontinuing hormonal treatment. 6
Clinical Implications for Surveillance
Most recurrences occur within 3 years of initial treatment, with the majority being symptomatic. 7
Key symptoms requiring prompt evaluation:
- Vaginal, bladder, or rectal bleeding 7
- Pelvic, abdominal, hip, or back pain 7
- Dysmenorrhea, dyspareunia, or dyschezia 8
- Decreased appetite or weight loss 7
Important Caveats
The definition of "recurrence" varies widely in the literature (0-89% reported rates), depending on whether it's defined as pain relapse, imaging findings, CA-125 elevation, or surgical confirmation. 9 The rates cited here use objective imaging or surgical confirmation, representing true anatomical recurrence rather than symptom recurrence alone.
Even with hysterectomy, approximately 25% of patients experience recurrent pelvic pain and 10% require additional surgery. 6 This underscores that endometriosis is a systemic disease that can persist even after definitive surgery.